Taken together, these studies suggest that BRCA1/BRCA2 mutations may serve as good predictive biomarkers for the response of pancreatic tumors to chemotherapeutic agents related to DNA damage. This evidence concerns the gene BRCA2 and pancreatic neoplasm.